Tempus AI, Inc. (NASDAQ:TEM) Director Jennifer A. Doudna Sells 1,320 Shares

Tempus AI, Inc. (NASDAQ:TEM) Director Jennifer A. Doudna sold 1,320 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $90.00, for a total transaction of $118,800.00. Following the sale, the director now owns 36,011 shares of the company’s stock, valued at $3,240,990. This trade represents a 3.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Tempus AI Price Performance

Shares of Tempus AI stock opened at $89.44 on Friday. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91.45. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The firm’s 50-day simple moving average is $46.60 and its 200-day simple moving average is $50.32.

Wall Street Analyst Weigh In

Several analysts recently weighed in on TEM shares. Loop Capital decreased their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. TD Cowen reissued a “buy” rating and issued a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Wolfe Research began coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Finally, Bank of America boosted their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Tempus AI currently has an average rating of “Moderate Buy” and a consensus price target of $58.55.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors have recently added to or reduced their stakes in TEM. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new position in shares of Tempus AI during the third quarter valued at $258,000. Clarus Group Inc. acquired a new stake in shares of Tempus AI during the 3rd quarter worth about $283,000. International Assets Investment Management LLC increased its position in shares of Tempus AI by 141,400.0% during the 3rd quarter. International Assets Investment Management LLC now owns 70,750 shares of the company’s stock worth $4,004,000 after purchasing an additional 70,700 shares in the last quarter. Dakota Wealth Management bought a new position in Tempus AI during the 3rd quarter valued at about $1,185,000. Finally, Janney Capital Management LLC acquired a new position in Tempus AI in the third quarter valued at about $385,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.